RESUMO
Shrinking lung syndrome (SLS) is a rare manifestation of systemic lupus erythematosus. We report the case of a patient with non-responding SLS (neither to glucocorticoids nor immunosupresors), who showed remarkable improvement after the onset of treatment with rituximab. Although there is a little evidence, treatment with rituximab could be proposed in SLS when classical treatment fails.
Assuntos
Antirreumáticos/uso terapêutico , Pneumopatias/tratamento farmacológico , Pneumopatias/etiologia , Lúpus Eritematoso Sistêmico/complicações , Rituximab/uso terapêutico , Dispneia/tratamento farmacológico , Dispneia/etiologia , Feminino , Humanos , Pessoa de Meia-Idade , SíndromeRESUMO
El síndrome del pulmón encogido (SPE) es una manifestación poco frecuente del lupus eritematoso sistémico. Exponemos el caso de una paciente afectada de SPE, refractario al tratamiento con glucocorticoides e inmunosupresores, que tras el inicio de tratamiento con rituximab presentó marcada mejoría de los síntomas. Aunque la evidencia es escasa, el tratamiento con rituximab podría ser propuesto en el SPE cuando fracasa el tratamiento clásico (AU)
Shrinking lung syndrome (SLS) is a rare manifestation of systemic lupus erythematosus. We report the case of a patient with non-responding SLS (neither to glucocorticoids nor immunosupresors), who showed remarkable improvement after the onset of treatment with rituximab. Although there is a little evidence, treatment with rituximab could be proposed in SLS when classical treatment fails (AU)